These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 26502938)

  • 1. Neuroregenerative Effect of Oxandrolone: A Case Report.
    Bianchi V; Marbini A
    Am J Case Rep; 2015 Oct; 16():763-7. PubMed ID: 26502938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The anabolic androgenic steroid oxandrolone in the treatment of wasting and catabolic disorders: review of efficacy and safety.
    Orr R; Fiatarone Singh M
    Drugs; 2004; 64(7):725-50. PubMed ID: 15025546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved functional recovery with oxandrolone after spinal cord injury in rats.
    Zeman RJ; Bauman WA; Wen X; Ouyang N; Etlinger JD; Cardozo CP
    Neuroreport; 2009 Jun; 20(9):864-8. PubMed ID: 19424096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of oxandrolone and exercise on muscle mass and function in children with severe burns.
    Przkora R; Herndon DN; Suman OE
    Pediatrics; 2007 Jan; 119(1):e109-16. PubMed ID: 17130281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Six-week improvements in muscle mass and strength during androgen therapy in older men.
    Schroeder ET; Vallejo AF; Zheng L; Stewart Y; Flores C; Nakao S; Martinez C; Sattler FR
    J Gerontol A Biol Sci Med Sci; 2005 Dec; 60(12):1586-92. PubMed ID: 16424293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistance training exercise and creatine in patients with Charcot-Marie-Tooth disease.
    Chetlin RD; Gutmann L; Tarnopolsky MA; Ullrich IH; Yeater RA
    Muscle Nerve; 2004 Jul; 30(1):69-76. PubMed ID: 15221881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anabolic effects of oxandrolone after severe burn.
    Hart DW; Wolf SE; Ramzy PI; Chinkes DL; Beauford RB; Ferrando AA; Wolfe RR; Herndon DN
    Ann Surg; 2001 Apr; 233(4):556-64. PubMed ID: 11303139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel Uses for the Anabolic Androgenic Steroids Nandrolone and Oxandrolone in the Management of Male Health.
    Wu C; Kovac JR
    Curr Urol Rep; 2016 Oct; 17(10):72. PubMed ID: 27535042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and pathological phenotype of the original family with Charcot-Marie-Tooth type 1B: a 20-year study.
    Bird TD; Kraft GH; Lipe HP; Kenney KL; Sumi SM
    Ann Neurol; 1997 Apr; 41(4):463-9. PubMed ID: 9124803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment with an anabolic agent is associated with improvement in respiratory function in persons with tetraplegia: a pilot study.
    Spungen AM; Grimm DR; Strakhan M; Pizzolato PM; Bauman WA
    Mt Sinai J Med; 1999 May; 66(3):201-5. PubMed ID: 10377553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxandrolone enhances skeletal muscle myosin synthesis and alters global gene expression profile in Duchenne muscular dystrophy.
    Balagopal P; Olney R; Darmaun D; Mougey E; Dokler M; Sieck G; Hammond D
    Am J Physiol Endocrinol Metab; 2006 Mar; 290(3):E530-9. PubMed ID: 16263771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic epidemiology of Charcot-Marie-Tooth disease.
    Braathen GJ
    Acta Neurol Scand Suppl; 2012; (193):iv-22. PubMed ID: 23106488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rehabilitation interventions for foot drop in neuromuscular disease.
    Sackley C; Disler PB; Turner-Stokes L; Wade DT; Brittle N; Hoppitt T
    Cochrane Database Syst Rev; 2009 Jul; (3):CD003908. PubMed ID: 19588347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurotrophin-3 therapy for Charcot-Marie-Tooth disease type 1A.
    Pleasure DE; Chance PF
    Neurology; 2005 Sep; 65(5):662-3. PubMed ID: 16157894
    [No Abstract]   [Full Text] [Related]  

  • 15. The natural history of Charcot-Marie-Tooth type 1A in adults: a 5-year follow-up study.
    Verhamme C; van Schaik IN; Koelman JH; de Haan RJ; de Visser M
    Brain; 2009 Dec; 132(Pt 12):3252-62. PubMed ID: 19843647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A beneficial effect of oxandrolone in the treatment of Duchenne muscular dystrophy: a pilot study.
    Fenichel G; Pestronk A; Florence J; Robison V; Hemelt V
    Neurology; 1997 May; 48(5):1225-6. PubMed ID: 9153447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgen therapy improves muscle mass and strength but not muscle quality: results from two studies.
    Schroeder ET; Terk M; Sattler FR
    Am J Physiol Endocrinol Metab; 2003 Jul; 285(1):E16-24. PubMed ID: 12637255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Charcot-Marie-Tooth disease type 1A presenting as calf hypertrophy and muscle cramps.
    Krampitz DE; Wolfe GI; Fleckenstein JL; Barohn RJ
    Neurology; 1998 Nov; 51(5):1508-9. PubMed ID: 9818900
    [No Abstract]   [Full Text] [Related]  

  • 19. A randomized efficacy and safety trial of oxandrolone in the treatment of Duchenne dystrophy.
    Fenichel GM; Griggs RC; Kissel J; Kramer TI; Mendell JR; Moxley RT; Pestronk A; Sheng K; Florence J; King WM; Pandya S; Robison VD; Wang H
    Neurology; 2001 Apr; 56(8):1075-9. PubMed ID: 11320181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NT-3 promotes nerve regeneration and sensory improvement in CMT1A mouse models and in patients.
    Sahenk Z; Nagaraja HN; McCracken BS; King WM; Freimer ML; Cedarbaum JM; Mendell JR
    Neurology; 2005 Sep; 65(5):681-9. PubMed ID: 16157899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.